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Among genetic alterations in human cancers, mutations in the tumor suppressor p53 
gene are the most common, occurring in over 50% of human cancers. The majority 
of p53 mutations are missense mutations and result in the accumulation of dysfunc-
tional p53 protein in tumors. These mutants frequently have oncogenic gain-of-function 
activities and exacerbate malignant properties of cancer cells, such as metastasis and 
drug resistance. Increasing evidence reveals that stabilization of mutant p53 in tumors 
is crucial for its oncogenic activities, while depletion of mutant p53 attenuates malignant 
properties of cancer cells. Thus, mutant p53 is an attractive druggable target for cancer 
therapy. Different approaches have been taken to develop small-molecule compounds 
that specifically target mutant p53. These include compounds that restore wild-type 
conformation and transcriptional activity of mutant p53, induce depletion of mutant p53, 
inhibit downstream pathways of oncogenic mutant p53, and induce synthetic lethality 
to mutant p53. In this review article, we comprehensively discuss the current strategies 
targeting oncogenic mutant p53 in cancers, with special focus on compounds that 
restore wild-type p53 transcriptional activity of mutant p53 and those reducing mutant 
p53 levels.
Keywords: mutant p53, depletion, compounds, reactivation, cancer therapy, gain of function, dominant negative, 
oncogenes
iNTRODUCTiON
The tumor suppressor p53 exerts its biological function by regulating transcription of numerous 
downstream target genes involved in cell cycle arrest, apoptosis, DNA repair, senescence, and 
metabolism as a transcription factor (1, 2). p53 is also directly recruited to the mitochondria and 
induces apoptosis independent of its function as a transcription factor (3). Under unstressed physi-
ological conditions, p53 expression is maintained at a low level, mainly by being degraded by its E3 
ubiquitin ligases, MDM2, Pirh2, and COP1 (4). Once cells are exposed to genotoxic stresses, p53 
is posttranslationally modified through phosphorylation and acetylation, becomes stabilized, and 
induces cell cycle arrest and/or cell death. When p53 activity is lost by gene deletion or mutations, 
normal cells lose the abilities to control their growth and death, leading to immortalization and 
ultimately cancer (5). The observation that over 50% of human cancers have mutations in the p53 
gene indicates the indispensability of intact p53 activity for suppressing tumor development (6).
Mutations in the p53 gene occur mainly in the DNA-binding domain, the majority of which 
are missense mutations, resulting in loss of function as a transcription factor and accumulation of 
dysfunctional p53 protein in tumors (7). Mutant p53 can be categorized roughly into two types: 
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DNA contact (class I) mutant where mutations are present on 
amino acids directly binding to the p53-responsive element in 
DNA (e.g., p53R273H and p53R280K) and conformational (class II) 
mutant in which mutations alter structure of p53 to abolish 
its DNA-binding ability (e.g., p53R175H and p53V143A) (8). Both 
the mutant types not only lose the transcriptional activity, 
but also have the dominant-negative (DN) activity by hetero-
oligomerizing with wild-type p53. Moreover, mutant p53 shows 
oncogenic gain-of-function (GOF) activities, such as enhanced 
tumor progression, metastatic potential, and drug resistance, 
when overexpressed even in cells lacking wild-type p53 (7). 
These findings are supported by the fact that p53 was originally 
appreciated as an oncogene, since researchers unknowingly used 
plasmids encoding mutations in the p53 gene. Thus, mutant p53 
functions as an oncogene and greatly contributes to malignant 
properties of cancer cells.
Disrupting specific mechanisms which cancer cells develop 
for their survival and growth is a rational approach to selectively 
kill cancer cells with minimal effects on normal cells. In this 
regard, mutant p53 is one of the best druggable targets, since 
over half of human cancers have p53 mutations, while normal 
cells mostly do not have mutations in the p53 gene (9). To exploit 
the frequent presence of mutant p53 in tumors and target mutant 
p53 in cancer therapy, two strategies including restoration of 
wild-type p53 transcriptional activity and depletion of mutant 
p53 have been extensively undertaken, in addition to inhibition 
of downstream target pathways involved in mutant p53 GOF and 
induction of synthetic lethality to mutant p53. Since mutant p53 
is generally accumulated in tumors (10), reactivating p53 activ-
ity can efficiently induce proliferation arrest and/or cell death of 
cancer cell. Specifically, in the late stage of tumor development, 
cancer cells express only mutant p53 with loss of heterozygo-
sity of the other wild-type p53 allele (11, 12). Such cells often 
have high metastatic and chemotherapy resistant properties. 
Hence, this p53 reactivation strategy is powerful to treat cancers 
expressing mutant p53. The other strategy to specifically deplete 
oncogenic mutant p53 in cancer cells should have minimal 
impact on wild-type p53, since depletion of wild-type p53 in 
normal and cancer cells can accelerate tumorigenesis or tumor 
progression. Accumulating studies suggest that knockdown of 
mutant p53 significantly reduces oncogenic potential of cancer 
cells expressing only mutant p53 (13–16), suggesting that malig-
nant properties of cancer cells are, at least partially, dependent 
on the presence of mutant p53. This could be simply due to the 
loss of oncogenic activity of mutant p53 or possibly because 
cancer cells are addicted to mutant p53 for their survival and 
proliferation. This strategy would work even better when cancer 
cells retain the wild-type p53 allele with the mutant p53 allele 
(heterozygous), since it can also restore wild-type p53 activity 
which is suppressed by the DN activity of mutant p53. Thus, 
depletion of mutant p53 is also an effective strategy to suppress 
tumor progression.
In this article, toward developing precision cancer medicine, 
we summarize updated information about compounds which 
can restore wild-type p53 activity, as well as those depleting 
mutant p53.
DRUGS/COMPOUNDS THAT ReSTORe 
wiLD-TYPe p53 ACTiviTY
Most p53 mutants lose their ability to bind with p53-response ele-
ments in DNA, thereby losing transcriptional activity and tumor 
suppressive function (17). However, the following evidence sug-
gests that sequence-specific p53 transcriptional activities can be 
restored from mutant p53: (1) many p53 mutants are temperature 
sensitive and restore the p53 activity at the permissive temperature 
(18, 19), (2) synthetic peptides, CDB3 and Peptide 46 which are 
derived from 53BP2 and C-terminal domain of p53, respectively, 
restore the sequence-specific DNA binding and transcriptional 
activity of p53 (20, 21), and (3) insertion of second-site mutations 
or a N-terminal deletion in several p53 mutants restore the p53 
transcriptional activities (22–24). Since the first p53-reactivating 
compound, CP-31398, was identified (17), investigators have 
made tremendous efforts to identify compounds that restore p53 
transcriptional activity. Major compounds related to mutant p53 
reactivation are listed in Table 1 and explained below.
CP-31398
CP-31398 (styrylquinazoline) was identified through a structure-
based screening as a compound which could restore native wild-
type p53 conformation from a denatured conformation in the 
DNA-binding domain, using a conformation specific antibody 
PAb1620. CP-31398 leads to increase in p21 mRNA expres-
sion in Saos-2 (p53-null) cells expressing p53V173A and p53R249S 
mutants, and inhibits tumor growth of A375.S2 (p53R249S) and 
DLD1 (p53S241F) cells (17). CP-31398 increases mRNA expression 
of MDM2 and p21 in multiple cancer cell lines (46). CP-31398 
also induces mitochondrial translocation of mutant p53R273H in 
A431 skin carcinoma cell line, leading to cytochrome c release 
and apoptosis (25). Intriguingly, CP-31398 cannot refold already 
misfolded mutant p53 proteins, since cycloheximide prevents the 
effect of CP-31398 on p53 restoration (23, 26). It also induces 
cell death in a p53-independent manner through free radical 
formation (27).
STiMA-1 (SH Group-Targeting Compound 
That induces Massive Apoptosis)
STIMA-1 [2-vinylquinazolin-4-(3H)-one] was identified as 
one of the CP-31398 derivatives, which induced mutant p53 
(p53R175H and p53R273H)-dependent growth suppression (28). Both 
CP-31398 and STIMA-1 bind to the cysteine residues in the core 
domain of mutant p53, leading to stabilization of wild-type p53 
conformation and subsequent restoration of transcriptional activ-
ity (28). STIMA-1 increases the DNA-binding ability of mutant 
p53, resulting in upregulation mRNA expression of p21, PUMA, 
and BAX, and leading to mutant p53-dependent apoptosis (28).
PRiMA-1 and PRiMA-1MeT/APR-246
PRIMA-1 [2,2-bis (hydroxymethyl)-3-quinuclidinone] was 
identified through a screening as a compound that suppressed 
proliferation of Saos-2 osteosarcoma cell line expressing p53R273H 
(Saos-2-p53R273H) with little effect on the parental Saos-2 cells. 
TABLe 1 | Compounds that induce reactivation of mutant p53.
Compound Type of mutant Mechanism Reference Structure
CP-31398 V173A, S241F, 
R249S, R273H





R175H, R273H Bind to the cysteine residues in the core domain and stabilize 
wild-type p53 conformation
(28)
PRIMA-1 and the 
methylated analog 
(APR-246/PRIMA-1MET)








Prevent unfolding of wild-type and mutant p53 and restore 
native wild-type p53 conformation
(31)
RITA (NSC652287) R175H, R248W, 
R273H, R280K
Restore p53 transcriptional activity and induce apoptosis (32, 33)
NSC319726/




Restore wild-type p53 conformation and activity with  
MDM2-dependent degradation
(34–36)
Chetomin (CTM) R175H Increase Hsp40 (DNAJB1) levels and Hsp40-p53R175H binding, 
restoring wild-type p53 conformation, activity, and MDM2-
dependent degradation
(37)
PK7088 Y220C Bind to a p53Y220C-specific surface cavity and stabilize p53Y220C 
with restored wild-type p53 conformation
(38)
Stictic acid (NSC87511) R175H, G245S Target cysteine 124 at the p53 core domain and restore  
wild-type p53 activity
(39)
p53R3 R175H, M237I, 
R273H
Restore sequence-specific DNA binding and p53 
transcriptional activities
(40)
SCH529074 R175H, L194F, 
R248W, R249S, 
R273H
Restore sequence-specific DNA binding and p53 
transcriptional activities
(41)
WR-1065 V272M Restore DNA binding and transcriptional activities of p53V272M (42–45)
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PRIMA-1 and its methylated analog PRIMA-1MET (also known 
as APR-246) not only enhance stability of wild-type p53 at 37°C, 
but also induce conformational change of p53R175H, leading to 
restoration of DNA-binding activity of p53R175H with increased 
MDM2 and p21 mRNA expression (23). Notably, PRIMA-1 
refolds previously accumulated unfolded mutant p53 (23). The 
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mechanisms underlying refolding of mutant p53 by PRIMA-1 
and PRIMA-1MET involve the conversion of these compounds to 
products which form adducts with thiol groups in the mutant p53 
core domain, leading to restoration of wild-type conformation 
and induction of apoptosis in tumor cells (29, 30). Several stud-
ies have successfully validated their tumor suppressive effects in 
mouse models of multiple types of cancer (47–50). Importantly, 
PRIMA-1MET is currently in clinical trials (51, 52).
MiRA-1 and its Structural Analogs
Using the same screening strategy as PRIMA-1, MIRA-1 
(NSC19630) was identified as a compound that suppressed pro-
liferation of Saos-2-p53R273H cells (31). MIRA-1 and its structural 
analogs MIRA-2 and MIRA-3 from the NCI repository inhibit 
proliferation of cancer cells expressing p53R175H and p53R273H (31). 
Both MIRA-1 and MIRA-3 also induce cell death in cancer cells 
expressing mutant p53 (31). Furthermore, MIRA analogs prevent 
unfolding of wild-type and mutant p53, and also restored native 
wild-type p53 conformation, leading to enhanced DNA-binding 
activity of mutant p53 (p53R175H and p53R248Q) and increase in 
mRNA expression of p53 downstream target genes, MDM2 and 
p21, in several mutant p53-carrying cancer cell lines (31). In vivo 
effects of MIRA analogs have also been confirmed in mouse 
models (31, 53).
RiTA (NSC652287)
NSC652287 [2,5-bis(5-hydroxymethyl-2-thienyl) Furan] is 
one of a series of thiophene derivatives and is known to inhibit 
tumor growth of renal cell carcinoma cells with DNA–protein 
cross-linking and upregulation of wild-type p53 and p21 (54, 55). 
NSC652287 (RITA: reactivation of p53 and induction of tumor 
cell apoptosis) is also identified through cell proliferation assay-
based screening using isogenic cell lines of HCT116 (wild-type 
p53 and p53-null) as a compound that suppresses the growth 
of HCT116 (wild-type p53) cells in a dose-dependent manner 
with minimum effects on HCT116 (p53-null) cells (56). Later, 
NSC652287/RITA was found to suppress the growth of cancer 
cell lines carrying various p53 mutants (p53R175H, p53R213Q/Y234H, 
p53R248W, p53R248Q, p53I254D, p53R273H, and p53R280K) by restora-
tion of p53 transcriptional activity (p21, NOXA, PUMA, and 
GADD45) and induction of apoptosis through upregulation of 
pro-apoptotic proteins and downregulation of several oncogenes 
or anti-apoptotic proteins (32, 33, 57). However, the exact mecha-
nism by which RITA activates both wild-type and mutant p53 to 
induce apoptosis remains unclear.
NSC319726/ZMC1 (Zinc 
Metallochaperone-1)
Zinc is required for proper folding of p53 protein, while lack of 
zinc in the central core domain of p53 leads to unfolding (23, 58, 
59). Also, addition of zinc to cells or its administration to mice 
carrying tumors are known to restore DNA-binding activity of 
mutant p53 (p53R175H and p53R273H) in cells and tumors, leading 
to tumor suppression (60). Thus, facilitating the binding of 
mutant p53 to zinc can be used to restore the proper folding and 
transcriptional activity of mutant p53 (34). Indeed, NSC319726 
[zinc metallochaperone-1 (ZMC1)], a thiosemicarbazone 
derivative, was identified in a screen of the NCI60 panel of 
human tumor cell lines as a compound that exhibited selective 
toxicity to cells carrying p53R175H with minimum effects on cells 
expressing wild-type p53 and other p53 mutants (p53R248Q and 
p53R273H) (35). NSC319726 restores the wild-type-like conforma-
tion of mutant p53 and upregulates p53 downstream target genes 
(p21, PUMA, and MDM2) through increasing ROS levels (35, 
36). It also reduces p53R175H levels, which is rescued by Nutlin-3a 
(35). Importantly, its administration induces greater toxicity in 
p53R172H/R172H (equivalent to human p53R175H) mice than in wild-
type mice in a dose-dependent manner (35). NSC319726 also 
suppresses tumor growth of TOV112D (p53R175H) cells in  vivo 
(35). Other thiosemicarbazone family members (NSC319726 
and NSC328784) also preferentially reduce cell viability of p53 
mutant cell lines (35).
Chetomin
Hiraki et  al. (37) performed high-throughput chemical library 
screening using a luciferase reporter with the p53 response ele-
ment of the PUMA promoter in H1299 (p53-null) cells carrying 
p53R175H, which identified chetomin (CTM) as a compound that 
increased luciferase activity dose-dependently. CTM suppresses 
cancer cell growth in  vitro and in  vivo more efficiently in cells 
expressing p53R175H with upregulation of MDM2, p21, and PUMA 
than those expressing wild-type p53 and p53R273H, as well as null 
for p53 (37). The effects of CTM on reduced p53R175H levels are 
dependent on MDM2 (37). Interestingly, CTM increases protein 
levels of Hsp40 (DNAJB1) and the binding of p53R175H to Hsp40, 
leading to restoration of wild-type p53 conformation and tumor 
suppression of cancer cells carrying p53R175H (37). However, CTM 
is also known to inhibit the hypoxia-inducible factor pathway 
by blocking the interaction of HIF proteins and their cofactor 
p300. Moreover, it suppresses in vivo tumor growth of HCT116 
(wild-type p53) cells and enhances radiosensitivity of cancer cells 
regardless of the p53 status (61–63). Thus, CTM has other func-
tion than mutant p53 reactivation.
PK7088
PK7088 [1-methyl-4-phenyl-3-(1H-pyrrol-1-yl)-1H-pyrazole] 
was identified as a compound that binds to a p53Y220C-specific 
surface cavity destabilizing this protein through protein-
observed NMR screening (38, 64). PK7088 stabilizes p53Y220C 
and restores wild-type p53 conformation. It is biologically active 
in cancer cells carrying p53Y220C mutant and induces G2/M 
arrest of the cell cycle and apoptosis with upregulation of NOXA 
and p21, as well as relocation of BAX to the mitochondria (38). 
PK7088 and Nutlin-3a cooperatively upregulate protein expres-
sion of p21 and NOXA (38). Crystal structure of p53-Y220C 
core domain with PK7242, a more soluble PK7088 analog, is 
also presented (38).
Stictic Acid (NSC87511)
A computational analysis of p53 structural models suggests that 
cysteine 124 of p53 is located at the center of a transiently open 
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binding pocket between loop L1 and sheet S3 of the p53 core 
domain (39). Based on the finding that additional mutation at 
cysteine 124 to alanine on p53R175H (p53C124A/R175H) abolished the 
effects of PRIMA-1 on the reactivation of p53R175H, Wassman et al. 
(39) performed an Ensemble-based virtual screening against this 
pocket and identified stictic acid as a p53 reactivation compound 
(39). Stictic acid stabilizes p53 in vitro and induces expression of 
p21 and PUMA in Saos2 (p53-null) cells expressing mutant p53 
(p53R175H and p53G245S) (39).
P53R3
The p53 reactivator (P53R3) is a compound identified through 
a screening using an in  vitro DNA-binding assay (40). P53R3 
restores sequence-specific DNA binding of several p53 mutants 
(p53R175H, p53M237I, and p53R273H) and induces p53-dependent anti-
proliferative effects with increase in mRNA expression of many 
p53 target genes, such as p21, GADD45, BAX, PUMA, PIG3, and 
MDM2 (40). It should be noted that P53R3 also increases mRNA 
expression of several p53 target genes (p21, GADD45, PUMA, 
and MDM2) in cancer cells expressing wild-type p53 (40).
SCH529074
The small molecule SCH529074 was identified by a DNA-binding 
assay-based screening as a compound that enabled p53R273H to 
bind to a consensus p53 DNA-binding site (41). SCH529074 
restores the PAb1620 epitope by acting as a chaperone and 
enhances DNA-binding activity of several p53 mutants (p53R175H, 
p53S241F, p53R248W, p53R249S, and p53R273H), leading to upregulation 
of p53 downstream target genes (p21, BAX, NOXA, cyclin G1, 
and PUMA), induction of proliferation arrest or apoptosis, and 
inhibition of in  vivo tumor growth of mutant p53-expressing 
cell lines (41). Additionally, SCH529074 binds to DNA-binding 
domain of p53 and inhibits ubiquitination and degradation of 
wild-type p53 by MDM2 (41).
wR-1065
WR1065 is an active form of amifostine and is used to protect tis-
sues against the damaging effects of radiation and chemotherapeu-
tic drugs (42). WR-1065 increases wild-type p53 activity through 
a JNK-dependent signaling pathway, but not through genotoxic 
mechanisms (42–44). It is also reported that WR-1065 restores 
wild-type p53 conformation of a temperature-sensitive p53V272M, 
leading to increase in the DNA-binding activity, transactivation 
of several p53 target genes (p21, GADD45, and MDM2), and cell 
cycle arrest in G1 phase (45).
COMPOUNDS THAT DePLeTe 
MUTANT p53
Although many p53-reactivating compounds seem to target more 
than one p53 mutant, it remains unclear if these compounds 
can reactivate all p53 mutants or specific mutant types. Also, 
PRIMA-1MET is the only drug currently under clinical trials. 
Thus, the development of p53-reactivating compounds remains 
challenging. Another approach to target oncogenic mutant p53 
is to discover compounds that specifically deplete mutant p53 
with little effect on wild-type p53. Rationale to develop mutant 
p53-depleting compounds is based on the following observa-
tions: (1) mutant p53 is inherently unstable, but once stabilized, 
it can accelerate tumor progression (10) and (2) knockdown of 
mutant p53 by small interference RNAs (siRNAs) or shRNAs 
reduces malignant properties of cancer cells (13–16), thus 
indicating that oncogenic potential of cancer cells are, at least 
partially, dependent on the presence of accumulated oncogenic 
mutant p53. Although the mechanisms behind stabilization or 
degradation of mutant p53 are not necessarily the same as those 
of wild-type p53 and remain elusive (5, 65), several compounds 
that induce mutant p53 degradation without altering wild-type 
p53 have been found. These compounds can be used as effective 
therapeutic strategies for both cancers carrying only mutant p53 
and those retaining wild-type p53 with mutant p53 as mentioned 
in the Introduction. Thus, compounds that specifically deplete 
mutant p53 are valuable for cancer therapy and also for elucidat-
ing the mechanisms of stabilization or degradation of mutant 
p53. Major compounds which deplete mutant p53 are listed in 
Table 2 and explained below.
Hsp90 inhibitors: Geldanamycin, 17-AAG, 
Ganetespib
Blocking the function of heat shock protein 90 (Hsp90) leads to 
depletion of several oncogenic proteins, such as Raf-1, ErbB2, and 
mutant p53 (66, 67), because Hsp90 contributes to accumulation 
of mutant p53 by inactivating p53 ubiquitin ligases, MDM2, and 
CHIP (68, 69). Treatment of cancer cells with 17-AAG, a Hsp90 
inhibitor and an analog of geldanamycin, promotes degrada-
tion of varieties of p53 mutants (p53R175H, p53L194F, p53R273H, and 
p53R280K) and decreases viability of cells carrying mutant p53 
(69). Importantly, another Hsp90 inhibitor, ganestespib, which 
is 50-fold more potent than 17-AAG in destabilizing mutant 
p53 with little effect on wild-type p53 levels, induces mutant 
p53 depletion with increased apoptosis in tumors in vivo in both 
p53R248Q Hupki (human p53 knock-in) and p53R172H knock-in 
mouse models (13). Ganetespib is currently under evaluation in 
clinical trials, including phase III for lung cancer (81–83).
Histone Deacetylase inhibitors: vorinostat/
SAHA, Romidepsin/Depsipeptide
The effects of histone deacetylase inhibitors (HDACi) on mutant 
p53 (p53R175H, p53R280K, and p53V274F/P223L) were first reported by 
Blagosklonny et al. (70). Later, two mechanisms describing the 
inhibition of HDAC8-mediated mutant p53 transcription (84) 
and mutant p53 destabilization through inhibition of HDAC6 
by HDACi are proposed (71). Specifically, suberoylanilide 
hydroxamic acid (SAHA, also known as vorinostat), a FDA-
approved HDACi that inhibits class I, II, and IV HDACs, induces 
degradation of mutant p53 by inhibiting HDAC6 activity, an 
essential positive regulator of Hsp90, and subsequent disruption 
of the HDAC6/Hsp90/mutant p53 complex, leading to mutant 
p53 ubiquitination by MDM2 and CHIP (71, 72). SAHA shows 
higher cytotoxic effects on cancer cells carrying mutant p53 than 
those having wild type or null for p53 (72). SAHA also sensitizes 
cancer cells to a topoisomerase inhibitor camptothecin in a 
mutant p53-dependent manner (71).
TABLe 2 | Compounds that deplete mutant p53.
Compound Type of mutant Mechanism Reference Structure
Hsp90 inhibitors: 17-AAG, 
geldanamycin, ganetespib
R175H, L194F, R248Q, R273H, 
R280K, R172H (mouse)






R175H, R280K, V247F/P223L Inhibit HDAC6 and disrupt the HDAC6/
Hsp90/mutant p53 complex
(70–72)
Arsenic compounds R175H, R248W, H179Y/R282W, 
R273H
Increase transcripts of Pirh2 and induce 
degradation of mutant p53
(73, 74)
Gambogic acid R175H, G266E, R273H, R280K Inhibit the mutant p53-Hsp90 complex and 
induce CHIP-dependent degradation
(75)
Spautin-1 R158lnF, R175H, S241F, R248Q, 
G266Q, R280L, R273H
Induce mutant p53 degradation via the CMA 
pathway activated by the suppression of 
macroautophagy under glucose-free and 
confluent conditions
(76, 77)
YK-3-237 V157F, M237I, R249S, R273H, 
R280K
Decrease mutant p53 levels through 
deacetylation at lysine 382 by activating 
SIRT1
(78)
NSC59984 R175L, R175H, S241F, R273H/
P309F
Induce MDM2-mediated mutant p53 
degradation and activate p73
(79)
Disulfiram (DSF) R273H Induce degradation of both wild-type p53 and 
p53R273H via the 26S proteasome pathway
(80)
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Arsenic Compounds
Arsenic trioxide (ATO), which is used to treat patients with 
acute promyelocytic leukemia (APL), binds to thiol groups in 
cysteine residues and induces degradation of proteins, such as 
promyelocytic leukemia protein (PML) and PML-retinoic acid 
receptor α (PML-RARα) fusion protein (85). It also activates 
wild-type p53 and upregulates p53 downstream target genes 
with induction of apoptosis (86). Yan et al. (73) asked the pos-
sibility of using arsenic compounds to target mutant p53 for 
degradation and found that ATO or sodium arsenite induced 
proteasomal-dependent degradation of several p53 mutants 
(p53R175H, p53H179Y/R282W, p53R248W, and p53R273H). ATO also 
increases transcripts of an E3 ubiquitin ligase Pirh2, leading 
to ubiquitination and degradation of several mutant p53 (74). 
However, it should be noted that arsenic compounds have 
carcinogenic effects and are known to induce several types of 
cancer (87).
Gambogic Acid
Gambogic acid (GA), a natural product derived from Garcinia 
hanburyi tree, induces apoptosis and inhibits tumor growth 
in vivo by upregulating wild-type p53 at protein levels (88). On the 
other hand, GA induces nuclear exports of mutant p53 (p53R175H, 
p53G266E, p53R273H, and p53R280K) for degradation by CHIP ubiq-
uitin ligase (75). GA prevents the mutant p53-Hsp90 complex 
formation but enhances the mutant p53-Hsp70 interaction (75). 
Biologically, GA reduces viability of mutant p53-expressing 
cancer cells and also increases cytotoxic effects of several 
December 2015 | Volume 5 | Article 2887
Parrales and Iwakuma Mutant p53 for Cancer Therapy
Frontiers in Oncology | www.frontiersin.org
chemotherapy drugs in human breast cancer MDA-MB-435 
(p53G266E) cell line (75).
Spautin-1
Spautin-1 is a derivative of MBCQ (4-((3,4-methylenedioxyben-
zyl)amino)-6-chloroquinazoline) which was identified as a small 
molecule that inhibited autophagy through an imaging-based 
screen using LC3-GFP as a marker (89). When cancer cells are 
placed in the nutrient-deficient environment, cells start autophagy 
to generate an alternative energy source to survive by degrading 
cellular proteins and organelles in the lysosome. Spautin-1 inhibits 
ubiquitin-specific peptidases, USP10 and USP13, and promotes 
the degradation of Vps34-PI3 kinase complexes, key regulators 
of autophagy, leading to inhibition of autophagy (89). Since 
USP10 also deubiquitinates wild-type p53, Spautin-1 promotes 
degradation of wild-type p53 (89, 90). Moreover, suppression of 
macroautophagy by Spautin-1 under glucose-free and confluent 
conditions is found to induce degradation of several p53 mutants 
(p53R158InF, p53R175H, p53R248Q, p53S241F, p53G266E, p53R280L, and 
p53R273H) through the chaperone-mediated autophagy (CMA) 
pathway (76). Spautin-1 also induces cell death under non-
proliferating condition only when cancer cells express mutant 
p53. This effect of Spautin-1 is independent of MDM2 and the 
ubiquitin–proteasome pathway, but is dependent on nuclear 
export of mutant p53 and the presence of Hsc70 (76, 77).
YK-3-237
YK-3-237 was originally identified as a compound that showed 
antiproliferative effects in different cancer cell lines, but its 
mechanism of action was unknown (91). Yi et al. (78) investigated 
the effects of this compound on the proliferation of breast cancer 
cell lines carrying different p53 status and found that YK-3-237 
preferentially inhibited the proliferation of breast cancer cell 
lines carrying mutant p53. YK-3-237 also decreased the levels 
of mutant p53 (p53V157F, p53M237I, p53R249S, p53R273H, and p53R280K) 
through reduction in acetylation at lysine 382 (K382) of mutant 
p53, a target site of a NAD+-dependent protein deacetylase SIRT1 
(also known as sirtuin 1) (78). Indeed, YK-3-237 activates SIRT1 
enzyme activity (78). Furthermore, treatment of triple-negative 
breast cancer cell lines with YK-3-237 results in induction of 
apoptosis and G2/M arrest of the cell cycle with increase in mRNA 
expression of NOXA and PUMA (78). However, the underlying 
mechanism remains unclear.
NSC59984
The small molecule NSC59984 was recently identified as a com-
pound that increased luciferase activity in SW480 (p53R273H/P309S) 
and DLD-1 (p53S241F) cells carrying a p53-responsive luciferase 
reporter construct (PG13) (79). NSC59984 increases mRNA 
and protein levels of several p53 targets, such as p21, PUMA, 
and NOXA, with increase in apoptosis. It should be noted that 
NSC59984 also induces apoptosis in cancer cells having wild type 
and null for p53, suggesting it has p53-independent effects on cell 
death (79). Moreover, NSC59984 induces degradation of several 
p53 mutants (p53R175L, p53R175H, p53S241F, and p53R273H/P309S) through 
MDM2-mediated ubiquitination, whereas it rather increases 
wild-type p53 levels (79). Importantly, the effects of NSC59984 
on p53 target gene expression and apoptosis are caused by activa-
tion of p73, rather than conformational changes of mutant p53 
(79). In in vivo xenograft mouse models, NSC59984 suppresses 
tumor growth of DLD-1 in a p73-dependent manner (79).
Disulfiram
Disulfiram (DSF) is used for the treatment of chronic alcoholism by 
inhibiting acetaldehyde dehydrogenase. DSF has also been under 
clinical trials for some types of cancer including glioblastoma 
multiforme and metastatic non-small cell lung cancer (92, 93). 
DSF and its metabolites which are strong ROS inducers contain 
a reactive disulfide bond and readily mediate thiol-conjugating 
reactions, leading to S-glutathionylation of cysteine residues 
in proteins (94, 95). Protein S-glutathionylation in response to 
oxidative stress can affect function and stability of target proteins 
(80, 96). Interestingly, p53 is found to be S-glutathionylated 
at cysteine residues 124 and 141 (97, 98). Paranjpe et  al. (80) 
reported that DSF and its derivative copper-chelated disulfiram 
(CuDSF) induced degradation of both wild-type p53 and p53R273H 
through the 26S proteasome pathway. However, DSF-induced 
protein degradation is not p53-specific, because it also induces 
degradation of other redox-regulated proteins, such as NF-κB 
subunit p50 and UBE1 (80).
OTHeR STRATeGieS TO TARGeT 
MUTANT p53 AND iTS ReLATeD GOF 
ACTiviTY
Compounds That induce Readthrough of 
Premature Termination Codons
About 8% of all the p53 mutations in human cancers are nonsense 
mutations, which results in the presence of premature termina-
tion codons (PTCs) (99). PTC leads to the mRNA degradation 
by the nonsense-mediated mRNA decay pathway or potential 
production of truncated proteins. However, aminoglycoside 
antibiotics (gentamicin, G418, and amikamicin) bind with the 
ribosomal RNA and promote readthrough of PTCs, leading 
to partial restoration of full-length protein production (100). 
Specifically, gentamicin, G418, and NMDI14 induce production 
of full-length functional p53 from p53Q192X, p53R213X, and p53E298X, 
leading to apoptosis induction in cancer cells carrying nonsense 
p53 mutations (101, 102).
Knockdown with Small interference RNA
Knocking down specific protein expression by siRNAs or 
shRNAs can be a specific and potent strategy to target cancers 
if methodologies of efficient in  vivo delivery are established 
(103). Indeed, downregulation of mutant p53 in T47D (p53L194F), 
MDA-MB-231 (p53R280K), and MDA-MB-468 (p53R273H) breast 
cancer cell lines induces PARP-dependent apoptosis (104, 105). 
In DU145 (p53P223L/V274F) prostate cancer cell line, downregula-
tion of p53P223L/V274F by siRNA induces cell cycle arrest at G1 and 
G2/M phases, as well as apoptosis in a PI3K/Akt-dependent 
manner (106). Also, silencing of mutant p53 in 5637 (p53R280T) 
and T24 (in-frame deletion of Y126) bladder cancer cell lines by 
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p53 siRNA induces G2 arrest of the cell cycle and apoptosis, and 
increases sensitivity to cisplatin (107). Thus, accumulated stud-
ies reveal that knockdown of mutant p53 by siRNAs or shRNAs 
reduces malignant properties of cancer cells. However, siRNAs 
for p53 used in aforementioned publications can also knockdown 
wild-type p53. Matinez et  al. (108) first developed a p53R248W-
specific siRNA which did not affect wild-type p53. Recently, 
our laboratory also developed siRNAs specific for p53R175H and 
p53R273H, which did not alter wild-type p53 expression levels 
(unpublished). We successfully showed reactivation of wild-type 
p53 and reduced cell proliferation and migration, following trans-
fection of these mutant-specific siRNAs in genetically engineered 
p53 heterozygous cancer cell lines (HCT116+/R248W, SW48+/R273H) 
(unpublished). Thus, the extraordinary sequence specificity of 
siRNA makes it an attractive tool for targeted cancer therapies.
Compounds That Affect Downstream 
Targets of Mutant p53
Another way to target oncogenic activity of mutant p53 is to reac-
tivate tumor suppressive pathways that are inhibited by mutant 
p53 or to inhibit tumor-promoting pathways that are activated 
by mutant p53.
Reactivate transcriptional activity (RETRA) was identi-
fied as a compound that increased β-galactosidase activity in 
A431 (p53R273H) human epidermal carcinoma cells expressing 
a p53-resonsive promoter-driven β-galactosidase construct, 
through high-throughput screening of a chemical library 
comprising of 46,250 compounds (109). RETRA increases 
β-galactosidase activity only in cancer cells carrying mutant p53 
(p53R248Q, p53R280L, and p53G266E) with increased mRNA expres-
sion of p21 and PUMA, but fails to do so in cells wild type or 
null for p53. Interestingly, the effects of RETRA are nullified by 
knockdown of p73, but not knockdown of p53 and p63 (109). 
Indeed, RETRA inhibits the binding of p53R273H with p73. RETRA 
also reduces A431 cell viability in a p73-dependent manner and 
reduces tumor growth in a xenograft model (109).
Statins are a class of compounds that inhibit 3-hydroxy-
3-methylglutaryl coenzyme A (HMG-CoA) reductase in the 
mevalonate pathway and have been used in the clinic to treat 
hypercholesterolemia. HMG-CoA reductase is the rate-limiting 
step in cholesterol synthesis and also regulates prenylation/
lipidation (farnesylation and geranyl-geranylation) of proteins. 
Prenylation facilitates attachment of target proteins to cell 
membranes which are involved in cellular adhesion, migration, 
and proliferation signaling (e.g., Rho, Rac, Cdc42, Ras) (110). 
Interestingly, knockdown of p53R273H significantly reduces mRNA 
expression of multiple enzymes involved in the mevalonate path-
way (16). Both knockdown of mutant p53 and inhibition of pro-
tein prenylation by statins or other compounds result in impaired 
growth of breast cancer cells in 3D culture (16). Mechanistically, 
mutant p53 binds to and activates SREBP, crucial transcription 
factors that regulate transcription of several enzymes involved 
in the mevalonate pathway, leading to enhanced prenylation 
of proteins associated with cancer progression and activation 
of prenylated proteins in breast cancer cells; hence, inhibition of 
protein prenylation by statins leads to reduced malignancy of 
human breast cancer cells (16). Importantly, the presence of p53 
mutation correlates with high expression of sterol biosynthesis 
genes in human breast tumors (16). Additionally, since nuclear 
localization and activation of the YAP and TAZ proto-oncogenes 
are regulated by prenylation and activation of Rho GTPases, 
statins could also suppress progression of mutant p53-expressing 
tumors by inhibiting YAP/TAZ activation by reducing protein 
prenylation of Rho GTPases, which is promoted by SREBP and 
its cofactor mutant p53 (111).
Compounds That induce Synthetic 
Lethality
Synthetic lethality is generally used for the condition where a 
mutation in a gene is not lethal by itself, but its combination with 
a drug or other gene mutations leads to cell death (112). Since 
over 50% of human cancers have mutations in the p53 gene, p53 
mutations become attractive targets for inducing synthetic lethal-
ity in tumors. In this regard, compounds that induce synthetic 
lethality to mutant p53 should selectively kill cancer cells express-
ing mutant p53 without affecting normal cells carrying wild-type 
p53. One compound that induces synthetic lethality to mutant 
p53 is UCN01, a protein kinase C inhibitor and a potent blocker of 
G2/M checkpoint of the cell cycle. Treatment of CA46 (p53R248Q) 
and HT29 (p53R273H) with UNO01 abrogates γ-irradiation-
induced G2/M arrest of the cell cycle and increases cytotoxicity 
(113). UCN01 also enhances cisplatin-induced cell death in 
MCF7-expressing human papillomavirus type-16 E6 (MCF7/E6) 
with little effect on parental MCF7 cells having functional p53 
(113). Another compound that is synthetic lethal to mutant p53 
is BI-2536, an inhibiter of polo-like kinase 1 (PLK1), an enzyme 
that controls G2/M checkpoint. Inhibition of PLK1 by BI-2536 
significantly enhances cytotoxic effect of ionizing radiation in 
DLD-1 (p53S241F) and p53R248W-overexpressing HCT116 cells, 
but it does not do so in parental HCT116 (wild-type p53) cells 
(114). Similar effects are observed with PD0166285, an inhibi-
tor of Wee1 kinase that regulates G2/M checkpoint. PD0166285 
sensitizes cancer cells (HT29: p53R273H and E6-overexpressing 
PA-1: wild-type p53) to radiation-induced death, whereas this 
effect is not detected in parental PA-1 cells (115). However, the 
observed synthetic lethality to mutant p53 is likely not dependent 
on oncogenic GOF activity of mutant p53, but rather depend-
ent on loss of wild-type p53 activity. Identification of synthetic 
lethality to mutant p53 alone, but not p53-null, could improve 
our understanding of oncogenic GOF activity of mutant p53 and 
contribute to the development of new compounds that target 
cancer cells carrying mutant p53.
SUMMARY AND FUTURe DiReCTiONS
Accumulated evidence has proven that small-molecule compounds 
can restore the transcriptional activity of mutant p53 or specifically 
deplete mutant p53. These compounds are expected to efficiently 
inhibit tumor growth with minimal effects on normal tissues. 
Several compounds listed in Tables 1 and 2 are already in clinical 
trials. Within p53 reactivators, PRIMA-1MET (also known as APR-
246) is the only drug under clinical trials (51, 52). On the other 
hand, amongst the compounds that deplete mutant p53, Hsp90 
inhibitors (81–83), HDAC inhibitors (116–118), ATO (119–121), 
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and DSF (92, 93, 122) are under clinical trials for cancer therapy. 
However, it is not completely understood whether these p53 reac-
tivators and mutant p53-depleting compounds have mechanisms 
of action on proteins or pathways other than mutant p53, if they 
have an impact on all p53 mutants or specific mutant types and 
their underlying mechanisms. Also, it would be important to 
determine any synergistic or additive effects of these compounds 
with conventional chemotherapy drugs on cancer cell survival and 
proliferation. Further studies to solve these concerns would help 
improving the efficacy and specificity of these compounds.
In order to better understand the mechanisms of action of com-
pounds that target mutant p53, it is important to determine whether 
they can directly bind with mutant p53 or proteins involved in the 
process of mutant p53 reactivation or depletion. There are several 
in vitro methodologies to determine compound–protein interaction, 
including Biacore assays, mass spectrometry-based approaches, and 
drug affinity responsive target stability (DARTS) assays (123–125). 
On the other hand, in vivo analysis is limited. Recently, Jafari et al. 
(126) reported a cell-based drug–protein interaction assay, called 
cellular thermal shift assay (CETSA). Investigating interactions 
between a compound and a specific protein in cells would signifi-
cantly improve our understanding of how efficiently and specifically 
the compound alters intracellular activity.
Biological effects of compounds that restore p53 activity are 
robust, since mutant p53 is usually accumulated in cancer cells, 
and hence these compounds have ample substrates to restore the 
p53 activity. On the other hand, compounds that deplete mutant 
p53 may not be as robust as those restoring the p53 activity; how-
ever, as mentioned in Section “Introduction,” survival and growth 
of cancer cells are frequently dependent on mutant p53 (oncogene 
addiction) (13, 14). Thus, simply depleting mutant p53 in tumors 
is likely sufficient to reduce tumor malignancy. Especially, when 
tumor cells retain the wild-type p53 allele, compounds depleting 
mutant p53 alone may be even more effective, since they could 
reactivate wild-type p53 by releasing from DN activity of mutant 
p53. These mutant p53-depleting compounds could also be used 
for prevention of tumorigenesis when patients inherently carry 
mutant p53, such as in the case of human tumor-prone disease 
Li–Fraumeni syndrome (LFS). Over 70% of LFS patients have p53 
mutations in their germlines (127), but mutant p53 is not always 
stable and accumulates mainly in tumors (10). A compound that 
depletes only accumulated mutant p53 in tumors could reduce 
risk of tumor development in LFS patients. The approach of 
mutant p53-specific knockdown by siRNAs or DNA oligomers 
could cause similar outcomes to those by mutant p53-depleting 
compounds. However, the major hurdle of this approach is effi-
cient delivery of these oligomers to all cancer cells, which need to 
be addressed prior to their consideration for clinical trials (103).
Other than compounds summarized in this review article, 
compounds that target inhibitors of p53, such as MDM2 and 
MDM4, are also powerful to reactivate p53 and are summarized 
in other review articles (128, 129). Also, induction of synthetic 
lethality for mutant p53 is another specific approach for cancer 
cells expressing mutant p53 (128, 130–132). Inhibitors of proteins 
associated with G2/M arrest of the cell cycle and mitotic check-
point appear to cause mitotic catastrophe in cancer cells lacking 
wild-type p53 activity.
In summary, discovering efficient and safe compounds that 
specifically target mutant p53 remains challenging. Hence, it is 
crucial to further understand how mutant p53 induces oncogenic 
function, to elucidate the exact mechanisms of mutant p53 
stabilization or degradation in tumors, and to identify mutant 
p53-specific downstream signaling pathways or binding partners. 
The battle with cancer is unexpectedly taking longer, with cancers 
being wily enough to escape from current available treatments 
and develop novel ways of surviving. Given that several mutant 
p53-targeting drugs are already undergoing clinical trials, the goal 
toward establishment of therapies to cure mutant p53-carrying 
cancers may be just on the horizon.
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